NasdaqGM:KEQU

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture products. More Details


Snowflake Analysis

Adequate balance sheet and overvalued.


Similar Companies

Share Price & News

How has Kewaunee Scientific's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: KEQU has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-0.2%

KEQU

1.6%

US Medical Equipment

2.3%

US Market


1 Year Return

-42.3%

KEQU

19.1%

US Medical Equipment

17.2%

US Market

Return vs Industry: KEQU underperformed the US Medical Equipment industry which returned 17.1% over the past year.

Return vs Market: KEQU underperformed the US Market which returned 15.8% over the past year.


Shareholder returns

KEQUIndustryMarket
7 Day-0.2%1.6%2.3%
30 Day-3.4%-2.3%-4.6%
90 Day-0.8%9.7%7.4%
1 Year-42.3%-42.3%20.1%19.1%19.8%17.2%
3 Year-68.9%-70.7%70.5%66.0%37.4%28.3%
5 Year-40.0%-46.4%145.9%127.1%83.8%63.0%

Price Volatility Vs. Market

How volatile is Kewaunee Scientific's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Kewaunee Scientific undervalued compared to its fair value and its price relative to the market?

0.65x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate KEQU's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate KEQU's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: KEQU is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: KEQU is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate KEQU's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: KEQU is good value based on its PB Ratio (0.7x) compared to the US Medical Equipment industry average (4x).


Next Steps

Future Growth

How is Kewaunee Scientific forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

24.3%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Kewaunee Scientific has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Kewaunee Scientific performed over the past 5 years?

-38.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: KEQU is currently unprofitable.

Growing Profit Margin: KEQU is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: KEQU is unprofitable, and losses have increased over the past 5 years at a rate of 38.4% per year.

Accelerating Growth: Unable to compare KEQU's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KEQU is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.8%).


Return on Equity

High ROE: KEQU has a negative Return on Equity (-15%), as it is currently unprofitable.


Next Steps

Financial Health

How is Kewaunee Scientific's financial position?


Financial Position Analysis

Short Term Liabilities: KEQU's short term assets ($58.5M) exceed its short term liabilities ($30.7M).

Long Term Liabilities: KEQU's short term assets ($58.5M) exceed its long term liabilities ($18.3M).


Debt to Equity History and Analysis

Debt Level: KEQU's debt to equity ratio (22.3%) is considered satisfactory.

Reducing Debt: KEQU's debt to equity ratio has reduced from 25.1% to 22.3% over the past 5 years.

Debt Coverage: KEQU's debt is not well covered by operating cash flow (15.3%).

Interest Coverage: Insufficient data to determine if KEQU's interest payments on its debt are well covered by EBIT.


Balance Sheet


Next Steps

Dividend

What is Kewaunee Scientific current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate KEQU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate KEQU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if KEQU's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if KEQU's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: KEQU is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of KEQU's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average management tenure


CEO

Thomas Hull (44 yo)

1.5yrs

Tenure

US$674,030

Compensation

Mr. Thomas D. Hull, III, has been President and Chief Executive Officer at Kewaunee Scientific Corporation since March 11, 2019 and served as its Chief Financial Officer since November 1, 2015 until April ...


CEO Compensation Analysis

Compensation vs Market: Thomas's total compensation ($USD674.03K) is about average for companies of similar size in the US market ($USD601.03K).

Compensation vs Earnings: Thomas's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Thomas Hull
President1.5yrsUS$674.03k0.075%
$ 18.7k
Donald Gardner
VP of Finance1.42yrsUS$512.96k0.014%
$ 3.4k
Ryan Noble
Vice President of Sales & Marketing - Americas2.17yrsUS$333.87k0.027%
$ 6.8k
Elizabeth Phillips
Vice President of Human Resources11.25yrsno data0.13%
$ 32.5k
Bhoopathy Sathyamurthy
MD of International Operations & VP of Kewaunee Scientific Corporation Singapore Pte. Ltd.no datano datano data
Keith Smith
Director of Metal Plant Operations and Facilities4.42yrsUS$260.43kno data

2.2yrs

Average Tenure

43.5yo

Average Age

Experienced Management: KEQU's management team is considered experienced (2.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Thomas Hull
President1.5yrsUS$674.03k0.075%
$ 18.7k
Keith Gehl
Independent Director5.42yrsUS$92.00k0.31%
$ 77.5k
David Rhind
Independent Chairman1.5yrsUS$94.50k4.84%
$ 1.2m
Margaret Pyle
Independent Director25.5yrsUS$87.00k1.96%
$ 484.7k
Donald Shaw
Independent Director7.25yrsUS$87.00k0.83%
$ 206.5k
John Russell
Independent Director9.33yrsUS$89.50k0.53%
$ 130.2k

6.3yrs

Average Tenure

64yo

Average Age

Experienced Board: KEQU's board of directors are considered experienced (6.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Kewaunee Scientific Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Kewaunee Scientific Corporation
  • Ticker: KEQU
  • Exchange: NasdaqGM
  • Founded: 1906
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$24.771m
  • Shares outstanding: 2.76m
  • Website: https://www.kewaunee.com

Number of Employees


Location

  • Kewaunee Scientific Corporation
  • 2700 West Front Street
  • Statesville
  • North Carolina
  • 28677
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
KEQUNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJan 1980

Biography

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture products. The company operates in two segments, Domestic and International. Its products ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/30 00:31
End of Day Share Price2020/09/29 00:00
Earnings2020/07/31
Annual Earnings2020/04/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.